Apellis Pharmaceuticals, Inc.
APLS
$22.07
$0.823.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 475.52% | -11.93% | -38.84% | 58.96% | 59.04% |
| Total Depreciation and Amortization | -25.82% | -0.67% | 0.45% | -6.09% | -1.08% |
| Total Amortization of Deferred Charges | -3.34% | 157.98% | 677.63% | 682.67% | 777.33% |
| Total Other Non-Cash Items | 2.59% | -21.87% | -24.83% | -19.51% | -2.47% |
| Change in Net Operating Assets | -316.69% | 396.84% | 110.05% | 166.68% | 209.37% |
| Cash from Operations | 218.13% | 153.30% | 59.84% | 119.78% | 120.17% |
| Capital Expenditure | -- | 45.56% | 97.27% | 78.95% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 45.56% | 97.27% | -600.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.82% | 27.22% | -97.03% | -93.95% | -55.60% |
| Repurchase of Common Stock | 71.43% | -- | 75.00% | -650.00% | -27.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 81.85% | -- |
| Cash from Financing | -68.80% | -84.56% | -99.75% | -2.22% | -55.76% |
| Foreign Exchange rate Adjustments | -87.28% | 100.29% | 271.77% | -265.24% | 137.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 196.47% | -66.17% | -108.86% | 114.20% | 122.47% |